“Dr. Khandelwal is an exceptional clinician and physician leader who has served his cardiac patients with great skill, compassion and innovation for more than two decades,” said Stephen Bailey, MD, Chair of the AHN Cardiovascular Institute.

PITTSBURGH (PRWEB)
June 15, 2023

Akshay Khandelwal, MD, MBA, FACC, FSCAI, an interventional cardiologist and physician leader with the Henry Ford Health system, has been named Chair of the Department of Cardiovascular Medicine at Allegheny Health Network (AHN).

As cardiovascular medicine chair, Dr. Khandelwal will lead a team of 67 employed physicians, 40 affiliated physicians and 23 fellows, ensuring the provision of advanced, high-quality cardiovascular medicine services at AHN’s hospitals and outpatient centers, and fortifying AHN’s relationship with Western Pennsylvania’s community hospitals and independent cardiology groups.

The Department of Cardiovascular Medicine is part of AHN’s Cardiovascular Institute. In his new role, Dr. Khandelwal will partner with colleagues within the Cardiovascular Institute and the AHN Department of Thoracic and Cardiovascular Surgery to promote multidisciplinary collaboration between AHN’s cardiologists and its cardiovascular and thoracic surgeons through all stages of the patient care journey, creating comprehensive care plans and determining the best care pathways for patients with heart disease.

He succeeds former cardiology chair Srinivas Murali, MD, who retired earlier this year.

“Dr. Khandelwal is an exceptional clinician and physician leader who has served his cardiac patients with great skill, compassion and innovation for more than two decades,” said Stephen Bailey, MD, Chair of the AHN Cardiovascular Institute. “We are thrilled that he will soon help lead our world-class heart program.”

At Henry Ford — a five-hospital heath network based in Detroit, Michigan — Dr. Khandelwal serves as Associate Medical Director of the Heart and Vascular Service Line, and he is among the senior staff at the Edith & Benson Ford Heart & Vascular Institute.

As an interventional cardiologist, Dr. Khandelwal specializes in treating heart disease with catheter-based techniques. His areas of expertise include complex coronary interventions, such as angioplasty and stent procedures, and diagnostic cardiology.

Dr. Khandelwal’s research has been widely published in professional and academic journals. He is also the incoming Treasurer for the American College of Cardiology, the premier, 54,000-member professional, education, and credentialing organization for heart specialists in the U.S. and 140 other countries.

“Over the decades, AHN and Allegheny General Hospital have built a reputation for excellence in the medical and surgical treatment of cardiovascular disease,” said Donald Whiting, MD, chief medical officer for AHN. “Dr. Khandelwal will add to that legacy in the years to come, and his academic, research, and clinical acumen will further advance AHN’s ability to deliver pioneering cardiovascular care that enhances the experience and outcomes of our patients, enabling them to live their best and healthiest lives.”

Dr. Khandelwal earned his medical degree from Bangalore University’s Sri Devaraj Urs Medical College in India, and he completed an internal medicine residency, chief residency, cardiology fellowship, and interventional cardiology fellowship at Henry Ford Hospital, formally joining the Henry Ford clinical staff as an attending physician thereafter.

In 2022, he also received a Physician Executive Master of Business Administration degree from the University of Tennessee’s Haslam College of Business. He is an associate professor at Wayne State University.

Dr. Khandelwal is board-certified in cardiovascular disease and interventional cardiology by the American Board of Internal Medicine.

“It’s an incredible honor to join a forward thinking, blended health organization like AHN and Highmark Health that is truly committed to transforming medicine,” Dr. Khandelwal said. “I’m also thrilled at the opportunity to work alongside Dr. Bailey and so many other talented and innovative heart specialists at AHN who have helped build a stellar legacy cardiovascular care excellence.”

About the Allegheny Health Network:

Allegheny Health Network (AHN.org) is an integrated healthcare delivery system serving the greater Western Pennsylvania region. The Network is composed of 14 hospitals, ambulatory surgery centers, Health + Wellness Pavilions, multiple employed physician organizations, home and community based health services, a research institute, and a group purchasing organization. The Network provides patients with access to a complete spectrum of advanced medical services, including nationally recognized programs for primary and emergency care, trauma care, cardiovascular disease, organ transplantation, cancer care, orthopedic surgery, neurology and neurosurgery, women’s health, diabetes, autoimmune disease and more. AHN employs approximately 22,000 people, has more than 2,600 physicians on its medical staff and serves as a clinical campus for Drexel University College of Medicine and the Lake Erie College of Osteopathic Medicine.

Share article on social media or email:

Throughout the entirety of this project, the Hammes team consistently brought detail-oriented and creative solutions to the table, always with the end goal in mind.

MILWAUKEE (PRWEB)
June 15, 2023

Hammes Healthcare, a leading provider of consulting and project delivery services, is honored to celebrate the ribbon-cutting ceremony for the new VHC Health Outpatient Pavilion in Arlington, Virginia.

Construction of the new 250,000-square-foot outpatient pavilion began in 2019 with the goal of expanding VHC Health’s outpatient capacity and improving access to care. The new pavilion is adjacent to VHC Health’s main campus and offers numerous outpatient services, including surgery, women’s imaging, pharmacy, an outpatient lab, endoscopy and physical therapy. A new 1,700-car parking garage was also constructed in conjunction with the new Outpatient Pavilion, increasing accessibility and expanding parking for the entire campus.

Hammes was engaged by VHC Health initially to develop options that would support the system’s goal of expanding ambulatory access to patients on the main campus. Hammes worked closely with VHC Health leadership throughout the approval process and has served as project manager for the last seven years.

“Throughout the entirety of this project, the Hammes team consistently brought detail-oriented and creative solutions to the table, always with the end goal in mind,” said Richard J. Krumenacker, PE, Vice President, Facilities, Construction & Health System Services for VHC Health. “They helped us navigate numerous challenges, including the aftermath of the pandemic and supply chain constraints, to successfully deliver this facility that will provide much-needed expanded patient care to the community.”

“As a resident of the Washington DC metro area for more than 20 years, I personally know many people who have and will continue to receive care at VHC. This organization has expanded its footprint and also its long-standing reputation and commitment as a leading provider of quality care to this community,” said Nancy Connolly, President of Hammes Healthcare. “It is a true joy, both personally and professionally, to celebrate this milestone with my fellow colleagues, project partners and VHC Health.”

About Hammes Healthcare

Hammes Healthcare is a national consulting firm that provides real estate and market strategy, facility planning, project management and development services to the healthcare industry. As a reflection of its commitment to the healthcare industry, Hammes has been recognized as one of the nation’s leading healthcare developers by Modern Healthcare’s Construction & Design Survey for 25 consecutive years—including 20 years as No. 1—and by Revista’s Outpatient Healthcare Real Estate Development Report. Headquartered in Milwaukee, Wisconsin, Hammes provides services through a network of regional offices strategically located across the United States. https://www.hammes.com/

Share article on social media or email:

Glucose accounts for a large percentage of the $28.9 billion home IVD testing market.

“The global Home IVD testing market was valued at $28.9 billion in 2022, with the largest portion of that glucose testing and COVID-19 testing.“ – Kalorama Information

ARLINGTON, Va. (PRWEB)
June 15, 2023

The Home in vitro diagnostic (IVD) testing market is not new, but it had primarily been limited to glucose and pregnancy testing. COVID-19 testing has opened the door for home infectious disease testing and more. The market is detailed in “At-Home Diagnostic Testing Markets and Trends (COVID-19, FOB, Glucose, HIV and Other Tests), 2023”, the latest report published by leading medical market research firm Kalorama Information.

The global Home IVD testing market was valued at $28.9 billion in 2022, with the largest portion of that attributed to glucose testing and COVID-19 testing. The Home IVD market increased 9% over 2021, largely due to increases in the infectious disease segment, namely COVID-19 testing sales. Although it is hard to predict the future of Home IVD diagnostic testing, Kalorama has attempted to provide the best trajectory for this market based on available data and industry information.

The Home IVD testing market is a growing market facilitated by the proliferation of COVID-19 tests that have entered the market since the pandemic began. This has spurred insurance companies to provide reimbursement for home COVID-19 tests, which could help to save money in the long run on health costs.

Advancements in technology have provided new methods of testing such as nasal and buccal swabs and increased accuracy of immunoassays and molecular tests. Some of the barriers to the market have been addressed but there is still more to be done.

Consumers are taking a greater role in their own healthcare with testing being a big part of that. Consumers also experienced growing confidence in performing their own tests due to the proliferation of COVID-19 tests during the pandemic. It is Kalorama Information’s assumption that telemedicine and internet connection have also played a role in consumer empowerment making it easier to reach the provider to discuss the home test results.

Growth of the Home IVD testing market will likely continue in the short term and has a very good foundation for continuing to grow in the future. At the present time, it is hard to speculate the long-term trajectory of Home IVD testing but there are positive signs that the market will continue to build on the successes of glucose, pregnancy and COVID-19 testing.

For more information or to purchase this market research report visit : https://kaloramainformation.com/product/at-home-diagnostic-testing-markets-and-trends-covid-19-fob-glucose-hiv-and-other-tests-2023/.

ABOUT KALORAMA INFORMATION

Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals. Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology. Comprised of industry-leading brands, Science and Medicine Group serves analytical instrument, life science, imaging, and clinical diagnostic companies by helping them create strategies and products to win markets and provide platforms to digitally engage their markets through a variety of innovative solutions. Kalorama Information produces 30 reports a year. The firm offers a Knowledge Center, which provides access to all published reports.

Share article on social media or email:

Often people know the best what they need, they just don’t often have access or the ability to talk about it without a guide. So we can be that guide.

GARERVILLE, Calif. (PRWEB)
June 15, 2023

Amber Bedell, the new owner of Singing Trees Recovery Center, is excited to announce that this week marks the official reopening of the Garberville, California facility.

After many members of the community were saddened by the news of Singing Trees Recovery Center shutting down last November after more than 30 years in business, Amber Bedell reached out to the owners about the possibility of selling the space to someone interested in relaunching the recovery facility. The previous owners were thrilled with Amber’s plan to reopen and reinvigorate the recovery center.

After purchasing the facility, Amber Bedell has been upgrading the center with new floors, fresh paint, and new furniture. Amber Bedell has also added a number of new staff members. Those who enter the Singing Trees Recovery Center will now have access to onsite counselors, psychiatric nurse practitioners, and substance abuse counselors. This expands on the previous model, which only provided substance abuse counselors.

Though there will be many of the same services offered at Singing Trees, Bedell notes the center is not a strictly 12-Step model, like NA or AA and will offer “a variety of modalities.” The center will still offer 12-Step materials and utilize some of those approaches, Bedell said, but will take bits from other recovery models and tailor a treatment plan to the individual. Additional treatment modalities available include: SMART recovery, Harm Reduction and brain based interventions designed to re-wire the reward pathway’s created by addition. Singing Tree’s under the umbrella of Pure Solution Family Services, Inc, owned by Amber Bedell is a community based program, with a focus on meeting each individual where they are. We use a holistic approach for treatment planning and aim to reduce the stigma associated with addiction by uncovering the trauma experiences, with a spirit of compassion.

“It’s just not a one-size-fits-all, cookie-cutter approach — we believe in co-creation and we believe in empowering people,” explains Amber Bedell.

Bedell continued, “Often people know the best what they need, they just don’t often have access or the ability to talk about it without a guide. So we can be that guide.”

Singing Trees Recovery Center officially reopens this week.

About Singing Trees Recovery Center:

Singing Trees Recovery combines the best of both medical and social model approaches to substance abuse treatment. The residential rehab reinforces 12-Step concepts and principles while engaging clients in intensive therapeutic activities designed to uncover their particular underlying trauma/attachment style, etc. When treatment is complete, the hope is that graduates will leave the facility armed with the tools necessary to maintain of lifetime of sobriety, as well as the ability to enjoy and embrace all that life has to offer.

Share article on social media or email:

“We’re thrilled to bring our hybrid model of expert RCM teams and AI to Home Health & Hospice providers. Our goal: help them address staffing challenges, optimize RCM workflows, reduce bad debt, improve cash flow, so they can focus on exceptional client care,” said Joey Graham, CRO at Prochant.

CHARLOTTE, N.C. (PRWEB)
June 15, 2023

Prochant, the only AI-driven home-based care reimbursement service, is proud to announce its expansion into the Home Health & Hospice industry. The company now offers a unique blend of outsourced Revenue Cycle Management (RCM) teams and AI-driven tools, all custom-tailored to meet the distinct needs of providers in this sector. With its proven track record in revenue cycle management for HME/DME businesses, infusion pharmacies, and specialty pharmacies, Prochant aims to transform the financial prospects of Home Health & Hospice providers. Home Health & Hospice providers often encounter complex challenges in managing their revenue cycle, which range from labor shortages, stringent compliance measures and regulatory adjustments to the fluctuating landscape of Medicare. With over two decades of industry knowledge and expertise, Prochant delivers a hybrid model of human expertise and AI-driven RCM services that amplify revenue, enhance cash flow, automate billing and collection operations, and significantly reduce staffing costs. The key features and benefits of Prochant’s RCM services for Home Health & Hospice providers include:

•     Prochant Intake: Let our team of reimbursement experts handle everything from incoming referrals to prior authorization.
• Prochant Billing: Improve your clean claim rate and simplify your billing process with the help of our experts.
• Prochant Collections: Use our AI-driven automation tools and analytics to reduce your DSO to less than 40 days and bad debt rate of 3% of less.

We’re thrilled to offer our proven hybrid model of dedicated expert RCM teams and enterprise-grade AI-driven automation for Home Health & Hospice providers,” said Joey Graham, Chief Revenue Officer at Prochant. “By utilizing our expertise, dedicated RCM teams, and AI technology, we’re empowering home-based care providers to overcome financial hurdles, tackle staffing challenges, and optimize medical billing workflows, thereby enabling them to focus on delivering exceptional client care.

Prochant’s blend of human expertise and AI-driven solutions continue to disrupt healthcare reimbursement operations, allowing providers to streamline their billing processes, minimize errors, decrease bad debt, and improve cash flows. As a HITRUST-certified company, Prochant upholds trust and credibility among all stakeholders, including employees, prospects, customers, and investors. To schedule a demo or learn more about Prochant’s services, please contact marketing@prochant.com or visit prochant.com.

ABOUT PROCHANT

Prochant is the only AI-driven reimbursement service provider in the home-based care industry. We deliver focused revenue cycle management (RCM) solutions to healthcare providers with 7 wholly-owned global delivery centers. Our expertise lies in providing end-to-end RCM for home-based care, infusion, and specialty pharmacies, consistently delivering exceptional results to some of the leading healthcare providers in the country. We harness specialized automation technology and deep industry knowledge to streamline the time-consuming and expensive reimbursement process. As a result, we help healthcare providers accelerate their collections, increase revenue, and reduce operational costs while managing risk. Prochant is HITRUST certified, the gold standard for HIPAA security.

Share article on social media or email:

“Babyscripts has spent nine years building the best-in-class remote monitoring solution for maternity care, working closely with our provider users to ensure that our solution fits seamlessly into their workflow and responds to the needs of their patients.”

WASHINGTON (PRWEB)
June 15, 2023

Babyscripts, the leading virtual care platform for managing obstetrics, announced today that it was recognized as a Top Company in Remote Patient Monitoring upon conclusion of extensive research and company outreach by AVIA Marketplace, the leading digital health marketplace.

Babyscripts offers a clinically-validated, obstetrics-specific solution for remote pregnancy and postpartum care. Through a mobile app and remote patient monitoring, it targets the problems generated from the critical shortage of obstetrical providers in the US, as well as systemic and structural failures that create barriers to care for low-income and minority women. Babyscripts has been instrumental in life-saving interventions for preeclampsia and postpartum hypertension; and among other outcomes, has demonstrated success in decreasing no-show rates, improving postpartum visit attendance, reducing the amount of time to identify preeclampsia, and eliminating racial inequities in blood pressure ascertainment.

“We’ve spent nine years building the best-in-class remote monitoring solution for maternity care, working closely with our provider users to ensure that our solution fits seamlessly into their workflow and responds to the needs of their patients,” said Anish Sebastian, CEO of Babyscripts. “This recognition from AVIA is a validation of the work that we’ve done, and will continue to do, to make better care accessible to all pregnant and postpartum mothers through remote monitoring.”

The Top Remote Patient Monitoring Companies Report represents the aggregation and analysis of client ratings and reviews as well as health system implementation data across the country and highlights broader industry trends to contextualize the impact the companies and products are currently having in the space. Given the complexity and evolving nature of remote patient monitoring, the 2023 refresh of this report helps define the remote patient monitoring landscape and how these solutions best support patient care.

“With the rise of Remote Patient Monitoring solutions, a transformative shift in patient care is imminent. Our report illuminates the trailblazers making significant strides in this field,” said Dhiraj Patkar, SVP of Digital Health Solutions at AVIA. “Our objective with the Top Remote Patient Monitoring Companies Report is to arm healthcare organizations with comprehensive insights and tools crucial for the successful deployment and expansion of these advanced digital solutions. Leveraging digital technologies, we can extend care access, optimize patient experiences and outcomes, and tackle the escalating challenges that healthcare providers encounter in today’s multifaceted landscape.”

AVIA Marketplace is where innovative health systems and hospitals go to find the right digital health solutions. It’s built to efficiently search vendors and guide informed decisions, with tools like product comparisons, match scores, report generators, peer reviews, and market insights.

Access the full report findings from AVIA Marketplace’s Top Remote Patient Monitoring Companies list here.

About Babyscripts

Babyscripts is delivering a new model for prenatal and postpartum care that is transforming the way expectant mothers use technology to work with their healthcare providers. Since 2014, we’ve delivered the most-implemented mobile clinical solution for remote monitoring in pregnancy, with the mission to eliminate maternal mortality and improve access to care for all mothers. For more information on our virtual care solution and to request a demo, visit babyscripts.com.

About AVIA

AVIA is the nation’s leading digital transformation partner for healthcare organizations. AVIA provides unique market intelligence, proven collaborative tools, and results-based consulting to help solve healthcare’s biggest strategic challenges. Learn more about AVIA and AVIA Marketplace, the industry’s premier marketplace for digital health innovation, at aviahealthinnovation.com. Follow us on LinkedIn and Twitter.

Share article on social media or email:

Immunotherapy is a rapidly evolving field. This guideline provides clinicians with trusted and up-to-date information with expert guidance on the nuances of the approved immunotherapy regimens.

MILWAUKEE (PRWEB)
June 15, 2023

The Society for Immunotherapy of Cancer (SITC), the world’s leading member-driven organization dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy, has published the first clinical practice guideline (CPG) focused on immunotherapy for the treatment of gynecologic cancer.

The new manuscript, “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancers”, was published in the Journal of ImmunoTherapy of Cancer (JITC), SITC’s peer-reviewed online journal, and it will be available in SITC’s mobile guidelines app.

“Immune checkpoint inhibitors have demonstrated strong activity in cervical and endometrial cancer,” said Mary (Nora) L. Disis, MD, FACP, co-Chair of the SITC Gynecologic Cancer Clinical Practice Guideline Expert Panel. “This has significantly changed how we treat these cancers and is offering extended survival for many patients compared to previous treatment options.”

While the integration of ICIs has undeniably improved patient outcomes, their usage in clinical practice necessitates careful consideration. Specific indications require PD-L1 expression or mismatch repair (MMR) status assessment, highlighting the critical importance of appropriate biomarker testing for each disease state. To address these complexities, the SITC Gynecologic Cancer Clinical Practice Guideline Expert Panel was assembled to develop evidence- and consensus-based recommendations, aiding clinicians in navigating the treatment landscape, biomarker testing, and other essential aspects such as considerations for special patient populations, quality of life concerns, and immunotherapy education for patients and caregivers.

“Immunotherapy is a rapidly evolving field. This guideline provides clinicians with trusted and up-to-date information with expert guidance on the nuances of the approved immunotherapy regimens,” said Kunle Odunsi, MD, PhD, co-Chair of the SITC Gynecologic Cancer Clinical Practice Guideline Expert Panel.

The manuscript, the latest installment in the ongoing series of SITC Cancer Immunotherapy Guidelines, is now available in the Journal for ImmunoTherapy of Cancer (JITC), SITC’s esteemed open access, peer-reviewed online journal. Furthermore, it will soon be accessible through SITC’s CPG Mobile App, ensuring widespread availability and accessibility.

“SITC’s clinical practice guidelines are a trusted and essential resource for clinicians seeking guidance on immunotherapy, developed by some of the most renowned experts in the field,” said SITC President Leisha Emens, MD, PhD. “Through the open-access publication in JITC, SITC’s free CPG Mobile App, and companion educational opportunities, SITC is committed to clinician education and improving patient care.”

In addition to the guideline, there are upcoming free live webinars offered by SITC and on-demand modules hosted on the SITC website focusing on topics within this guideline and providing attendees the opportunity to ask questions of expert faculty. View the page here to stay up-to-date with future webinar details.

About SITC

Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn and YouTube.

About SITC’s Clinical Practice Guidelines

The SITC Cancer Immunotherapy Guidelines Program is a collection of clinical practice guidelines (CPGs) developed by multidisciplinary panels of experts who draw from practical experience as well as evidence in the published literature and clinical trial data to provide recommendations for clinicians on how and when to use immunotherapy to help improve outcomes for patients with cancer. SITC’s guidelines provide recommendations on topics including selection of appropriate immunotherapy treatments, toxicity management, biomarkers, and considerations for patient quality of life. SITC’s expanding catalogue of CPGs spans disease-state specific guidelines for several solid tumors, hematologic malignancies, and toxicity-specific guidelines to assist clinicians with the management of immune-related adverse events. You may access the entire series of CPGs in the Journal for ImmunoTherapy of Cancer (JITC), the society’s open access, peer-reviewed online journal, or in the CPG Mobile App.

About JITC

Journal for ImmunoTherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of the Society for Immunotherapy of Cancer featuring an impact factor of 12.485. The journal publishes high-quality articles on all aspects of tumor immunology and cancer immunotherapy, on subjects across the basic science-translational-clinical spectrum. JITC publishes original research articles, literature reviews, position papers and practice guidelines, and case reports; invited commentaries may also be commissioned by the journal editors. These articles, freely accessible at jitc.bmj.com, make JITC the leading forum for tumor immunology and cancer immunotherapy research. Follow JITC on Twitter @jitcancer.

Share article on social media or email:

11th Annual International Conference of the Pan Asian Academy of Facial Plastic and Reconstructive Surgery

WILTON, Conn. (PRWEB)
June 15, 2023

Board-certified otolaryngologist and facial plastic and reconstructive surgeon Neil A. Gordon of the New England Surgical Center, LLC, located at The Retreat at Split Rock, was honored to be invited as a highly-respected international expert on facial rejuvenation to the 11th Annual International Conference of the Pan Asian Academy of Facial Plastic and Reconstructive Surgery. The prestigious 2023 International Conference of Facial Plastic Surgery featured an 11-Day Facial Plastic Surgery Course in beautiful Singapore.

The Pan Asian Academy of Facial Plastic and Reconstructive Surgery (PAAFPRS) promotes the training and practices of Facial Plastic Surgery in Asia (FPSA). It is a member of the International Federation of Facial Plastic Surgery Societies (IFFPSS). The international conference and gala dinner occurred at the Regent Hotel on February 21-22, 2023, with combined lectures and structured instruction at the Auditorium/Surgical skills laboratory, at Khoo Teck Puat Hospital and Carlton Hotel in Singapore on February 18-28, 2023.

During the 11-Day Facial Plastic Surgery Course, Dr. Neil A. Gordon, M.D., served as an international teacher of honor. During the course on aesthetic surgery on February 21-22, he shared his clinical expertise and advanced research on deep-plane facelift techniques, brow lifting, and other innovations in aesthetic surgery. Dr. Gordon also demonstrated the deep-plane facelift and other strategic methods during the cadaver dissections.

Dr. Gordon’s Advanced Techniques

Dr. Neil A. Gordon specializes in facial rejuvenation and rhinoplasty and only performs facial and neck surgery. He is a widely-recognized pioneer and expert in deep-plane facelifts. Dr. Gordon has created advanced facial rejuvenation procedures and is an educator to plastic surgeons and medical professionals worldwide, featuring educational presentations for advanced deep-plane rhytidectomy and vertical galea advancement displaying innovative brow lift techniques.

Vertical Platysma Advancement/Advanced Deep-Plane Facelift

Dr. Gordon has been invited to lecture on his advanced deep-plane facelift techniques every year since 1996, both nationally and internationally. He specifically focuses on modifications and nuances of the original method to achieve specific goals utilizing a strategic approach for revision and redo-facelifts. Dr. Gordon’s technical improvements have led to the development of vertical platysma advancement.

The deep-plane rhytidectomy (facelift) and vertical platysma advancement use sophisticated procedural techniques to reposition sagging soft tissue without unnatural tightening or pulling. Dr. Gordon is widely admired for his ability to adjust and alter overly pulled facial skin and eyebrows. The deep-plane or vertical platysma advancement procedure creates pleasing, outstanding results and reverses poor SMAS facelift results.    

Vertical Galea Advancement

Dr. Gordon has developed the advanced vertical galea procedure, which replaces the eyebrow lift. It rejuvenates the forehead area and opens the brows to frame the eyes, rather than raising the brows and creating an unnatural appearance, as seen after a traditional brow lift. The goal of the treatment is to achieve the same soft tissue tone in the upper and lower face; the procedure is frequently performed with a deep-plane facelift.

Instead of lifting the brows, Dr. Gordon skillfully raises the galea, the underlying layer, to invisibly improve the upper face while creating total facial balance as the adjustment assists nasolabial folds and the neck. Dr. Gordon trains others to perform this revolutionary, natural-looking treatment, which can be combined with an eyelid lift.

Expanding Deep Plane Facelift Technique Internationally

Dr. Gordon has surgeons from five continents who have traveled to observe vertical platysma advancements in deep-plane facelifts. He is credited with expanding the technique in the USA, Europe, and Australia. Dr. Gordon, along with distinguished peers, helps to educate and advocate for the best medical procedures using advanced technology.

Dr. Gordon is considered an international expert in revision facelift surgery. He has published modifications for the deep-plane technique on the neck and mid-face and has contributed to multiple academic books. He has numerous publications and medical literature, lectures internationally, and the popular TV show “Botched” was based on his revision work.

Many patients travel internationally to visit Dr. Gordon at the beautiful, state-of-art retreat at Split Rock Surgical Center in Wilton, CT, and two additional offices. Dr. Gordon is passionate about training other top surgeons and was honored to share his pioneering work at the 11th International Conference of Facial Plastic and Reconstructive Surgery in Singapore.

###

To learn more about board-certified otolaryngologist and facial plastic and reconstructive surgeon, Dr. Neil Gordon, M.D., call (203) 834-7700 or contact us at The Retreat At Split Rock in Wilton, CT, Greenwich, CT, and New York, NY.

Share article on social media or email:

Join this webinar and discover outsourcing options for highly potent oral solid dose therapies, and learn how CDMOs can transfer, handle and deliver their product to clinic and to market.

TORONTO (PRWEB)
June 15, 2023

How does a CDMO ensure the successful development and manufacture of breakthrough discoveries? Could drug development projects be translated into safe, effective and accessible drug products for patients, whilst ensuring a greater speed to market for sponsor organizations? In this webinar, the featured speakers share CDMO insights on outsourcing high potent oral solid dose late-stage development.

The development and manufacture of drug products containing highly potent active pharmaceutical ingredients (HPAPIs) is in demand. Recent data suggest that between 2023 and 2030, the small molecule drug discovery market will register a compound annual growth rate (CAGR) of around eight percent. This is particularly relevant in the field of oncology, which accounts for around 35 percent of small molecule drug candidates, around half of which contain HPAPIs.

The development of targeted therapies and precision medicines has revolutionized cancer treatment, resulting in more effective and potentially less toxic therapeutic options for patients. Furthermore, regulatory agencies including the US Food and Drug Administration (FDA) have implemented accelerated approval pathways, fostering innovation and promoting faster commercialization of novel oncology drugs. In this dynamic landscape, the role of CDMOs becomes even more critical.

In this webinar, the speakers will explain what the gold standard is for an outsourcing partner for high potent oral solid dose therapies, the necessary equipment and facilities and how to maintain flexibility in a multi-product facility. They will also discuss a real-world case study, highlighting the importance of selecting the right CDMO for high potent outsourcing.

Join this webinar and discover outsourcing options for highly potent oral solid dose therapies, and learn how CDMOs can transfer, handle and deliver their product to clinic and to market.

Join experts from PCI Pharma Services, David O’Connell, Director of Scientific Affairs; and Lauren Angove-Parry, Director of Development, for the live webinar on Thursday, June 29, 2023, at 1pm EDT (10am PDT).

For more information, or to register for this event, visit Outsourcing High Potent Oral Solid Dose Late-Stage Development: CDMO Insights.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email: